Digital biomarkers market poised for $17.73b expansion by 2031 amidst remote monitoring surge

Clinical trials expand use of real-world data capture through digital monitoring tools.

The digital biomarkers market is projected to grow to $17.73b by 2031, with a compound annual growth rate of 19.1%, as clinical research increasingly integrates remote monitoring and digital endpoints into trial design, according to a MarketsandMarkets report.

The market growth is driven by rising use of software platforms and digital technologies in clinical trials to support continuous patient monitoring and endpoint measurement.

Clinical research applications are expected to record significant growth as trials adopt remote data capture and digital biomarker tools for continuous monitoring.

The report states that about 59% of participants have implemented remote data capture, including digital biomarkers, in studies.

The shift is visible across clinical trial activity, where thousands of studies each year increasingly incorporate wearable devices, sensors, and remote monitoring tools to capture real-world patient data.

More than 30,000 to 35,000 clinical trials are initiated annually across phases, with Phase II and Phase III trials accounting for a large share of activity, the report notes.

By therapeutic area, cardiovascular conditions accounted for the largest share of the digital biomarkers market in 2025, supported by the global burden of cardiovascular disease, which causes around 17.9 million deaths annually, or about 32% of all deaths worldwide.

The report notes increasing use of wearable-based tools to monitor heart rate, rhythm, and activity in both clinical research and real-world settings.

By type, physiological biomarkers accounted for the largest share of 40.6% of the market in 2025. By application, clinical research led adoption trends, supported by increasing use of digital endpoint analytics in trial monitoring systems.

North America accounted for the largest regional share of 48.1% of the global market in 2025, supported by high clinical trial activity and adoption of digital endpoints in research institutions and healthcare systems.